FDA-approved gout drug shows promise in fighting COVID-19

319
SHARES
2.5k
VIEWS

You Might Also Like


– Advertisement –


Probenecid has been on the market for over 40 years

– Advertisement –

A gout drug approved by the US Food and Drug Administration (FDA) may reportedly show promise in fighting the coronavirus.

According to a recent study by the University of Georgia (UGA) published in Nature Scientific Reports, probenecid has potent antiviral properties that make the oral drug a prime candidate to fight not only SARS-CoV-2 infection but also other common and deadly respiratory viruses. make.

advertisement

COVID-19 has killed as many Americans as the 1918-19 flu

The school notes that probenecid is primarily used to treat arthritis and has been on the market for more than 40 years with minimal side effects for patients.

– Advertisement –

“There’s really nothing we can do to safely fight these viruses,” Ralph Tripp, lead author of the study and Ralph Tripp, a GRA eminent scholar of vaccine and therapeutic studies in the UGA College of Veterinary Medicine, said in a statement. “This antiviral works for all the RNA respiratory viruses we’ve tested, including SARS-CoV-2. RSV, the coronavirus, and the flu all spread in the same season. The bottom line is that you don’t have this one. Using oral medication can potentially reduce infection and disease.”

To be effective, probenecid stops viral replication, preventing it from infecting a person’s cells.

In the trial, UGA said, the drug worked as a prophylactic before exposure to the virus and as a post-exposure treatment, noting that the drug has also been shown to be effective in fighting RSV in vitro.

TrippBio used animal model – hamsters Against SARS-CoV-2 and flu.

The university said, “Although the drug will primarily be used once a person is positive for the virus, the prognostic findings mean that even people with known risks could potentially take the drug to prevent getting sick. ”

FDA panel endorses PFIZER’s COVID-19 vaccine booster for people 65 and older, high-risk patients

So far, the COVID-19 pandemic has killed more than 676,000 Americans, According to data from Johns Hopkins University.

Apart from this, 42,292,350 confirmed cases have been reported in America so far.

Treatment for people seriously ill due to COVID-19 is still limited.

UGA notes that current treatments include remdesivir and monoclonal antibodies. There is only remdesivir received federal approval For the treatment of COVID-19.

“These treatments have shown some effectiveness against SARS-CoV-2, but they are very expensive and very hard to come by,” Tripp said. “In fact, there are only a handful of alternatives that can really be used because of cost, restricted IV use, and lack of access. It’s not very useful to the world.”

The UGA compared the reuse of remdesivir to fight COVID-19 with potentially reusing probenecid with a prescribed pill, and suggested that probenecid could potentially enhance the effectiveness of other treatments as well.

Researchers are investigating which dose of probenecid may be most effective in fighting the virus, and Tripbio is reportedly set to begin clinical trials of the drug by the end of the year.

Side effects of probenecid include nausea, dizziness, vomiting and headache. According to the Atlanta Journal-Constitution.


– Advertisement –

Related News

Next Post

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending News